Header Logo

Connection

Lora Bailey-Downs to Cell Line, Tumor

This is a "connection" page, showing publications Lora Bailey-Downs has written about Cell Line, Tumor.
Connection Strength

0.274
  1. Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One. 2014; 9(5):e98624.
    View in: PubMed
    Score: 0.087
  2. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem. 2013 Mar 01; 21(5):1312-23.
    View in: PubMed
    Score: 0.079
  3. Identification of novel drugs to target dormant micrometastases. BMC Cancer. 2015 May 14; 15:404.
    View in: PubMed
    Score: 0.023
  4. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May; 353(2):392-404.
    View in: PubMed
    Score: 0.023
  5. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
    View in: PubMed
    Score: 0.022
  6. Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor. Bioorg Med Chem Lett. 2013 Jun 15; 23(12):3561-4.
    View in: PubMed
    Score: 0.020
  7. Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.